Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 4
Submit an article Journal homepage
407
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Emerging cognitive enhancing drugs

Jerry J Buccafusco Director, Regents' Professor of Pharmacology and Toxicology, Alzheimer's Research Center, Medical College of Georgia, Department of Pharmacology and Toxicology, 1120 – 15 Street, Augusta, Georgia 30912-2300, USA +1 706 721 6355; +1 706 721 9861; [email protected]; Charlie Norwood Veterans Administration Medical Center, Augusta, Georgia, 30904, USA
, PhD
Pages 577-589 | Published online: 22 Sep 2009

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Wito Richter, Frank S. Menniti, Han-Ting Zhang & Marco Conti. (2013) PDE4 as a target for cognition enhancement. Expert Opinion on Therapeutic Targets 17:9, pages 1011-1027.
Read now
Niels Plath, Linda Lerdrup, Peter Hjørringgaard Larsen & John Paul Redrobe. (2011) Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions. Expert Opinion on Investigational Drugs 20:6, pages 795-811.
Read now

Articles from other publishers (11)

Xuemei Wei, Guoqi Yu, Hualiang Shen, Yanjuan Luo, Tianbo Shang, Runpu Shen, Meiyang Xi & Haopeng Sun. (2023) Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement. Bioorganic Chemistry 130, pages 106278.
Crossref
Lingmin Chen, Jiao Jiao & Yonggang Zhang. (2022) Therapeutic approaches for improving cognitive function in the aging brain. Frontiers in Neuroscience 16.
Crossref
Simon E Ward, Mark H Harries, Laura Aldegheri, Andrea M Bradford, Elisa Ballini, Lee Dawson, Laurent Lacroix, Joanne Pardoe, Kathryn Starr, Annette Weil, Kerry Waters, John R Atack & Marie Woolley. (2019) Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile. Journal of Psychopharmacology 34:1, pages 93-102.
Crossref
Michael H. Irwin, Walter H. Moos, Douglas V. Faller, Kosta Steliou & Carl A. Pinkert. (2016) Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Drug Development Research 77:3, pages 109-123.
Crossref
John W. Wright, Leen H. Kawas & Joseph W. Harding. (2015) The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Progress in Neurobiology 125, pages 26-46.
Crossref
Rita U Ostrovskaya, Yulia V Vakhitova, Uliyana Sh Kuzmina, Milyausha Kh Salimgareeva, Liana F Zainullina, Tatiana A Gudasheva, Vener A Vakhitov & Sergey B Seredenin. (2014) Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Journal of Biomedical Science 21:1.
Crossref
Andrea Cavalli & Maria Laura Bolognesi. 2012. Polypharmacology in Drug Discovery. Polypharmacology in Drug Discovery 441 458 .
Anthony L Albiston, Shanti Diwakarla, Ruani N Fernando, Simon J Mountford, Holly R Yeatman, Broden Morgan, Vi Pham, Jessica K Holien, Michael W Parker, Philip E Thompson & Siew Yeen Chai. (2011) Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. British Journal of Pharmacology 164:1, pages 37-47.
Crossref
Alvin V. TerryJr.Jr., Patrick M. Callahan, Brandon Hall & Scott J. Webster. (2011) Alzheimer's disease and age-related memory decline (preclinical). Pharmacology Biochemistry and Behavior 99:2, pages 190-210.
Crossref
Donald J. AbrahamJ. Ellis Bell & Jessica K. Bell. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 369 402 .
Roland W. Bürli, Elizabeth Thomas & Vahri Beaumont. 2010. Neurodegenerative Diseases. Neurodegenerative Diseases 1 56 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.